Company: BGLC
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001477932-25-002725
Chunk: 238

Company: BioNexus Gene Lab Corp
Filing Date: 2025-04-15
Form: 10-K
Item: Item 10
Chunk 238
---
 CORP. 

CONSOLIDATED BALANCE SHEETS 

AS OF DECEMBER 31, 2024 AND 2023 

(Currency expressed in United States Dollars (“US$”)) 

(Audited)

    As of     December 31,  December 31,   Note  2024  2023 STOCKHOLDERS’ EQUITY         As at December 31, 2024, common stock, no par value; 300,000,000 shares authorized and 17,967,663 shares outstanding, and preferred stock, no par value; 30,000,000 shares authorized and no shares outstanding. As at December 31, 2023, common stock, no par value; 300,000,000 shares authorized and 17,667,663 shares outstanding, and preferred stock, no par value 30,000,000 shares authorized and no shares outstanding (on a post-reverse stock split basis)*.  12  $17,332,315  $17,191,315 Additional paid in capital      (5,011,891)  (5,011,891)Accumulated deficit      (3,442,620)  (1,844,278)Accumulated other comprehensive losses      (555,000)  (677,294)TOTAL STOCKHOLDERS’ EQUITY      8,322,804   9,657,852              TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY     $10,433,848  $11,399,793 

* Issued and outstanding shares of common stock have been adjusted for the periods prior to July 20, 2023, to reflect the 12-for-1 reverse stock split effected on that date on a retroactive basis as described in Note 12.

See accompanying notes to the consolidated financial statements.

 F-5Table of Contents

BIONEXUS GENE LAB CORP.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME/(LOSS) 

FOR THE YEAR ENDED DECEMBER 31, 2024 AND 2023 

(Currency expressed in United States Dollars (“US$”)) 

(Audited)

     Year ended      December 31,    Note  2024